Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/27623

Title:	Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients.
Authors:	Miravitlles, Marc Gáldiz, Juan B Huerta, Alicia Villacampa, Alba Carcedo, David Garcia-Rio, Francisco View more
Keywords:	COPD cost-effectiveness analysis cost-utility analysis tiotropium umeclidinium/vilanterol View more
Mesh:	Administration, Inhalation Aged Bronchodilator Agents Cost-Benefit Analysis Drug Combinations Female Forced Expiratory Volume Humans Longitudinal Studies Male Quality-Adjusted Life Years Severity of Illness Index Spain Symptom Assessment Treatment Outcome Benzyl Alcohols Chlorobenzenes Pulmonary Disease, Chronic Obstructive Quinuclidines Tiotropium Bromide View more
Issue Date:	2016
Citation:	Int J Chron Obstruct Pulmon Dis.2016;(11):123-32
Abstract:	Umeclidinium/vilanterol (UMEC/VI) is a novel fixed dose combination of a long-acting muscarinic receptor antagonist (LAMA) and a long-acting beta 2 receptor antagonist (LABA) agent. This analysis evaluated the incremental cost-effectiveness ratio (ICER) of UMEC/VI compared with tiotropium (TIO), from the Spanish National Health System (NHS) perspective.
PMID:	26848262
URI:	https://hdl.handle.net/20.500.12530/27623
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. La Paz > Artículos Hospitales > H. U. La Paz > Artículos

Files in This Item:

File	Description	Size	Format
PMC4723026.pdf		1.09 MB	Adobe PDF	View/Open